Women’s reproductive health diagnostics

Diagnostics

Looking for:Co-Founder, CSO, Founder

Innovations in healthcare are reshaping how we diagnose gynecologic conditions like endometrial cancer, endometriosis and adenomyosis. Our groundbreaking approach focuses on non-invasive sampling coupled with advanced biomarker analysis for early detection, especially among underserved populations. By leveraging integrated technologies, we aim to revolutionize women's health, offering timely diagnoses, improving outcomes, and ultimately saving lives. Join us in our mission to make early detection of gynecologic conditions accessible to all women, regardless of their background or resources.

Contact About This Opportunity

Contact

Leah Langlais

Mgr, Venture Development , Tech Launch Arizona

LeahL@tla.arizona.edu

(520) 626-0639

The Problem

Many gynecologic conditions are only investigated once symptoms manifest. At that point, diseases might have progressed to a point when significant surgical interventions are required. Current diagnostics require painful, anxiety-provoking, invasive surgery or biopsy, which impact accessibility and require visits to the clinic. The traumatic and time-consuming aspects of these diagnostics also lead to avoidance of these examinations.

The Solution

Our proposed new solution to address existing invasive diagnostic methods, is to use non-invasive, self-collected cervicovaginal secretion samples and to create biomarker panels to detect endometrial cancer and other uterine conditions sensitively and specifically.

The Opportunity

Our novel self-collection method for endometrial cancer, endometriosis and adenomyosis will improve detection in ALL women, but particularly in underserved and rural populations and decrease health inequities. Our endpoint is to create an at-home kit that provides more empowerment in women’s reproductive care.
In the USA alone, economic burden of endometriosis itself, including direct healthcare cost and indirect productivity loss when women are building their careers, is estimated as high as $78-111 billion annually.

Status

Clinical studies identified biomarker candidates for gynecologic diseases using minimally-invasive physician-collected cervicovaginal lavage samples. Next steps include validation in self-collected samples and to establish the predictive power of the biomarkers for various gynecologic diseases prior to initiating required regulatory steps.

Meet the Team

Melissa Herbst-Kralovetz PhD

Professor
College of Medicine - Phoenix

Peter Nestler PhD

Mentor
Tech Launch Arizona

Contact us today.

Talk to a Tech Launch Arizona Venture Development Manager to learn more and get connected to the inventor.

Leah Langlais

Mgr, Venture Development
Tech Launch Arizona

LeahL@tla.arizona.edu

(520) 626-0639

Check out more Diagnostics startups.

View All Startups & Inventions

Diagnostics

Looking for:Co-Founder, CSO, Founder

Women’s reproductive health diagnostics

Diagnostics Medical Devices

Looking for:CEO / Business Lead, Co-Founder

Tonometer for TCS diagnosis

Occult Tethered Cord Syndrome (TCS) is a serious medical condition often detected before birth. If the spinal cord is not free it can result in several other urological problems and can result in a life-long disability.

High throughput screening for aging-related drug discovery utilizing C. elegans

Diagnostics Pharma

Looking for:CEO / Business Lead

High throughput screening for aging-related drug discovery utilizing C. elegans

Senfina offers in vivo whole life drug discovery services for aging and age-related diseases based on a multi-feature high-throughput imaging platform using C. elegans as a model organism.